Navigation Links
Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
Date:9/20/2010

pound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.KERYX CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel. 212.531.5965E-mail: lfischer@keryx.com
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015 The Dohmen Company ... , Ph.D., MBA as Chief Science Officer (CSO) ... newly created role, Dr. Floyd will lead Dohmen,s ... portfolio of pre-commercial and post approval outsourced services ... medical communications.  Dr. Floyd brings decades of experience ...
(Date:9/1/2015)... Sept. 1, 2015   Medfusion, Inc., ... relationship between doctors and patients, today announced a ... N.C. -based venture capital firms.   ... association with Bull City Venture Partners and Hatteras ... Founder and Executive Chairman. "Both firms, experience working ...
(Date:9/1/2015)... CA (PRWEB) , ... September 01, 2015 , ... ... and colleagues from University of California Los Angeles, Boston University School of Medicine, ... Prevention appears in PLOS One, the world’s first multidisciplinary Open Access journal. ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply Chain Resiliency ... and resiliency practitioners with luminaries and thought leaders to advance the professional discipline ... their innovations and performance excellence. At that time its principle sponsor, Resilinc ...
Breaking Biology Technology:Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... Brain Metastases, PALO ALTO, Calif., Sept. 2 ... radiosurgery treatments for,multiple brain metastases using new RapidArc ... ). The MIMA Cancer Center in Melbourne,Florida and ... able to treat brain metastases more quickly and ...
... BMRN ) today announced that Jean-Jacques,Bienaime, Chief Executive ... 3rd Annual Citi Biotech Day in New York City ... Interested parties may access a live audio webcast of ... website, http://www.BMRN.com .,A replay of the call will ...
... development milestone payment to InterMune - ... to lead ITMN-191 program in Phase 2 -, BRISBANE, ... announced that InterMune has earned a $15 million,development milestone under ... NS3 protease inhibitor compound ITMN-191,(referred to as R7227 at Roche), ...
Cached Biology Technology:Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 4BioMarin to Present at the Citi Biotech Day 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Hole Research Center are analyzing the surprising results of the ... rainforest. , From January 2000 to July 2004, rainfall was ... of the Tapajós National Forest, in Brazil. A total of ... by 6' clear plastic panels suspended 3 to 12 feet ...
... Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska ... a strategic alliance designed to improve healthcare by ... tools for better diagnosis, prognosis, and treatment. , ... genetic analyses and measurement of gene expression in ...
... have discovered an important chemical in the brain's ... symptoms of opioid drugs like morphine and heroin. ... chemical--called a transporter--could relieve some of the early ... shaking, and jumpiness. Such drugs could become part ...
Cached Biology News:World's largest rainforest drying experiment completes first phase 2World's largest rainforest drying experiment completes first phase 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3Key Trigger Of Opioid Withdrawal Symptoms Found 2